Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GH – Research Report), Insmed (INSM – Research Report) and MacroGenics (MGNX – Research Report).
Guardant Health (GH)
Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Guardant Health yesterday and set a price target of $28.00. The company’s shares closed last Thursday at $19.44, close to its 52-week low of $15.81.
According to TipRanks.com, Ryskin is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $37.22 average price target, implying a 102.7% upside from current levels. In a report issued on April 29, Canaccord Genuity also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Insmed (INSM)
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Insmed, with a price target of $55.00. The company’s shares closed last Thursday at $26.38.
According to TipRanks.com, Fauth is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $46.50.
MacroGenics (MGNX)
In a report released yesterday, Stephen Willey from Stifel Nicolaus downgraded MacroGenics to Hold, with a price target of $7.00. The company’s shares closed last Thursday at $14.67.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MacroGenics with a $18.25 average price target, which is a 24.4% upside from current levels. In a report released yesterday, BMO Capital also downgraded the stock to Hold with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GH:
- Guardant Health Earnings Report: Is it a Beat?
- Guardant Health price target lowered to $30 from $45 at Canaccord
- Guardant Health assumed with a Buy at Craig-Hallum
- FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23
- Guardant Health to present data on epigenomics at 2024 AACR meeting
